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Frontline nilotinib in patients with chronic myeloid leukemia
in chronic phase: results from the European ENEST1st study
A Hochhaus1, G Rosti2, NCP Cross3, JL Steegmann4, P le Coutre5, G Ossenkoppele6, L Petrov7, T Masszi8, A Hellmann9, L Griskevicius10,
W Wiktor-Jedrzejczak11, D Rea12, D Coriu13, TH Brümmendorf14, K Porkka15, G Saglio16, G Gastl17, MC Müller18, P Schuld19,
P Di Matteo20, A Pellegrino20, L Dezzani20, F-X Mahon21, M Baccarani2 and FJ Giles22
The Evaluating Nilotinib Efﬁcacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with
newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep molecular response (MR4 (BCR-ABL1⩽ 0.01% on the
International Scale or undetectable BCR-ABL1 with ⩾ 10 000 ABL1 transcripts)) at 18 months was evaluated as the primary end point,
with molecular responses monitored by the European Treatment and Outcome Study network of standardized laboratories. This
analysis was conducted after all patients had completed 24 months of study treatment (80.9% of patients) or discontinued early. In
patients with typical BCR-ABL1 transcripts and ⩽ 3 months of prior imatinib therapy, 38.4% (404/1052) achieved MR4 at 18 months.
Six patients (0.6%) developed accelerated or blastic phase, and 13 (1.2%) died. The safety proﬁle of nilotinib was consistent with
that of previous studies, although the frequencies of some nilotinib-associated adverse events were lower (for example, rash,
21.4%). Ischemic cardiovascular events occurred in 6.0% of patients. Routine monitoring of lipid and glucose levels was not
mandated in the protocol. These results support the use of frontline nilotinib, particularly when achievement of a deep molecular
response (a prerequisite for attempting treatment-free remission in clinical trials) is a treatment goal.
Leukemia advance online publication, 3 November 2015; doi:10.1038/leu.2015.270
INTRODUCTION
Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the
treatment of patients with newly diagnosed Philadelphia
chromosome-positive (Ph+) chronic myeloid leukemia in chronic
phase (CML-CP) or Ph+ CML in accelerated phase (AP) or CP that is
resistant to or intolerant of prior therapy, including imatinib.1
Throughout 6 years of follow-up in the pivotal trial of frontline
nilotinib vs imatinib for patients with CML-CP (Evaluating Nilotinib
Efﬁcacy and Safety in Clinical Trials–Newly Diagnosed Patients
(ENESTnd)), nilotinib showed improved efﬁcacy over imatinib,
including earlier and deeper molecular responses.2–7 ENESTnd met
its primary end point, with statistically signiﬁcantly higher rates of
major molecular response (MMR; BCR-ABL1⩽ 0.1% on the Interna-
tional Scale (IS)) at 12 months with nilotinib 300mg twice daily
(44%) and nilotinib 400mg twice daily (43%) than with imatinib
(22%; P o0.001 vs either nilotinib arm).5 Moreover, progression to
AP or blastic phase (BP) tended to be less common with nilotinib;
by the 6-year data cutoff, 11 (nominal P= 0.0661 vs imatinib), 6
(nominal P=0.0030 vs imatinib) and 21 patients in the nilotinib
300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib
arms, respectively, progressed to AP/BP on study.6 Although the
total number of deaths on study was similar in the nilotinib
300-mg twice-daily and imatinib arms (by the 6-year data cutoff:
nilotinib 300-mg twice-daily, 21; nilotinib 400-mg twice-daily, 11;
imatinib, 23), fewer patients in the nilotinib arms than in the
imatinib arm died owing to advanced CML (6, 4 and 16,
respectively).6
The safety proﬁle of nilotinib is distinct from that of imatinib. In
ENESTnd, nausea, diarrhea and muscle spasms were the most
common adverse events (AEs) reported with imatinib, whereas rash
and headache were most common with nilotinib; although not
among the most common AEs, cardiovascular events were also
more frequent with nilotinib.3–7 In contrast to the trend for fewer
deaths with the higher dose of nilotinib vs the lower dose,
cardiovascular events were less common with the lower nilotinib
dose.6
ENEST1st was a phase 3b, multicenter, single-arm, open-label
study investigating the efﬁcacy and safety of nilotinib 300mg
twice daily (the recommended starting dose for patients with
newly diagnosed CML-CP1) in a large population of patients with
newly diagnosed Ph+ or Ph− BCR-ABL1+ CML-CP. Because
achievement of a deep molecular response is a key eligibility
criterion for attempting treatment-free remission (TFR) in clinical
trials,8–13 ENEST1st was designed with an emphasis on evaluating
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rates of deep molecular responses achieved with frontline
nilotinib. Although the most appropriate depth of response (for
example, molecular response 4 (MR4; BCR-ABL1IS⩽ 0.01%), mole-
cular response 4.5 (MR4.5; BCR-ABL1IS⩽ 0.0032%) or deeper) at
which to attempt TFR remains unknown, TFR following achieve-
ment of sustained MR4 is being investigated in ongoing
studies12,13; thus the ENEST1st primary end point analysis (rate
of MR4 at 18 months) provides an indication of the proportion of
nilotinib-treated patients who could be expected to meet the
eligibility requirements for such studies. In addition to evaluating
deep molecular responses, ENEST1st was the ﬁrst study to
evaluate the association between baseline European Treatment
and Outcome Study (EUTOS) risk score14 and nilotinib efﬁcacy and
the ﬁrst study to conduct molecular monitoring using a network of
IS-standardized laboratories, with 14 EUTOS laboratories partici-
pating. Here the ﬁnal results of ENEST1st are reported, based on
analyses conducted after all patients completed 24 months of
study treatment or discontinued early.
METHODS
Patients, study design and treatments
Adults (aged ⩾ 18 years) with newly diagnosed (⩽6 months), cytogeneti-
cally conﬁrmed Ph+ CML-CP or Ph− BCR-ABL1+ CML-CP were eligible for
enrollment. World Health Organization performance status ⩽ 2 was
required. Patients previously treated with hydroxyurea for 46 months
and imatinib for43 months were excluded. Patients were also excluded if
they had known impairments in cardiac function (including left ventricular
ejection fraction o45%, complete left bundle branch block, right bundle
branch block plus left anterior hemiblock/bifascicular block, ventricular-
paced pacemaker, congenital long QT syndrome, history or presence of
clinically signiﬁcant ventricular or atrial tachyarrhythmia, clinically signiﬁ-
cant resting bradycardia, QTcF4 450ms, myocardial infarction within the
past 12 months or other clinically signiﬁcant heart disease), history of acute
or chronic pancreatitis, impaired gastrointestinal function, concurrent
uncontrolled medical conditions that would present unacceptable safety
risks or compromise compliance with the protocol, major surgery within the
past 2 weeks or not recovered from side effects of surgery or concomitant
treatment with medications with the potential to prolong the QT interval or
known to be strong inducers or inhibitors of cytochrome P450 3A4.
All enrolled patients were treated with nilotinib at a starting dose of
300mg twice daily, for up to 24 months. Dose escalation was not allowed.
Dose interruptions were recommended for patients with study drug-
related, clinically signiﬁcant, nonhematological, noncardiac grade 2/3 AEs
or study drug-related grade 3/4 events related to white blood cells or
platelets. Recommendations for treatment resumption/dose reduction
were as follows: following the ﬁrst and second occurrences, resume
treatment with nilotinib 600mg/day upon improvement to grade o2
(nonhematological) or o3 (hematological); following the third occurrence,
resume treatment with nilotinib 450mg/day upon improvement to grade
o2 (nonhematological) or o3 (hematological), escalating to 600mg/day
after 1 week; following the fourth occurrence, resume treatment with
nilotinib 300mg/day upon improvement to grade o2 (nonhematological)
or o3 (hematological), escalating to 600mg/day after 1 month (escalation
for hematological events only); following the ﬁfth occurrence (or following
any study drug-related, clinically signiﬁcant, nonhematological grade 4 AE),
stop treatment and contact the study management committee. For
patients with corrected QT interval (QTc) prolongation from 480 to 499ms,
nilotinib dose interruption followed by resumption at 450mg/day upon
improvement to QTc⩽ 450ms was recommended; for patients with QTc
prolongation to ⩾ 500ms or with signiﬁcant cardiac conduction or rhythm
abnormalities, permanent discontinuation of nilotinib was recommended.
Assessments
BCR-ABL1 transcript type was determined by multiplex PCR at baseline.15
Molecular responses were assessed every 3 months during study
treatment using real-time quantitative PCR (RQ-PCR) at designated EUTOS
laboratories standardized to the IS. Deep molecular responses were scored
in accordance with the EUTOS recommendations in place at the time.16
MR4 was deﬁned as detectable BCR-ABL1IS⩽ 0.01% or undetectable BCR-
ABL1 in samples with ⩾ 10 000 ABL1 transcripts. Samples with a mean of
o10 000 ABL1 transcripts, or with a total ofo10 000 ABL1 transcripts in
the case of undetectable BCR-ABL1, were considered unevaluable for
MR4. MR4.5 was deﬁned as detectable BCR-ABL1IS ⩽0.0032% or undetect-
able BCR-ABL1 in samples with ⩾32 000 ABL1 transcripts. Samples with a
mean of o32 000 ABL1 transcripts, or with a total of o32 000 ABL1
transcripts in the case of undetectable BCR-ABL1, were considered
unevaluable for MR4.5.16
Bone marrow cytogenetic assessments were performed ⩽8 weeks before
the ﬁrst dose of nilotinib and at months 3 and 6 and every 6 months
thereafter until MMR was achieved or the patient discontinued nilotinib.
Cytogenetic assessments were performed and analyzed locally using standard
methods; ﬂuorescence in situ hybridization analyses were not allowed.
End points and deﬁnitions
The primary end point was the rate of MR4 at 18 months. Secondary end
points included the rates of complete cytogenetic response (CCyR; 0% Ph+
metaphases), MMR, MR4 and MR4.5 at and by 12 and 24 months;
progression to AP/BP; progression-free survival; overall survival (OS); and
safety. Patients who discontinued study treatment early were followed for
survival for up to 24 months; data regarding other outcomes (including
progression) were not collected after discontinuation of study treatment.
Progression-free survival was deﬁned as the time from the ﬁrst dose of
study treatment until documented disease progression or death owing to
any cause. OS was deﬁned as the time from the ﬁrst dose of study
treatment until death owing to any cause at any time (including after
discontinuation of study treatment). Patients were monitored for AEs
throughout study treatment and for up to 28 days following the last dose
of study drug. AEs were assessed according to the Common Terminology
Criteria for Adverse Events version 4.0.17 AE types included in the deﬁnition
of ischemic cardiovascular events (subdivided into three groups: peripheral
artery disease, ischemic heart disease, and ischemic cerebrovascular
events) are detailed in Supplementary Table S1.
Statistical analyses
All patients who received ⩾ 1 dose of study treatment were included in the
intent-to-treat and safety populations. Patients with typical BCR-ABL1
transcripts (that is, b2a2 and/or b3a2) and ⩽3 months of prior imatinib
treatment were included in the molecular analysis population for
evaluating molecular response rates (patients with atypical BCR-ABL1
transcripts were excluded because standard RQ-PCR methodology was not
optimized for detection of atypical BCR-ABL1 transcripts; patients with
43 months of imatinib therapy (a protocol violation) were excluded to be
as conservative as possible in analyzing the efﬁcacy of frontline nilotinib by
avoiding potential confounding effects of prior imatinib). Patients with
typical BCR-ABL1 transcripts, no prior imatinib exposure and evaluable RQ-
PCR assessments at 3 months were included in the landmark analysis
population; patients who had already achieved the target response (MMR,
MR4 or MR4.5, respectively) at 3 months were excluded from the landmark
analyses of MMR, MR4 and MR4.5 rates over time. Patients with Ph+
metaphases detected at screening or without evaluable cytogenetic
analyses at screening but with Ph+ metaphases detected at a later time
point were included in the cytogenetic analysis population for evaluating
rates of CCyR (patients without conﬁrmed Ph+ disease were unevaluable
for CyR and were excluded from the analysis of CCyR rates).
For calculation of response rates ‘at’ a designated time point, patients were
considered responders only if an assessment at that time point showed
achievement of the response. Response rates ‘by’ a designated time point
were calculated as cumulative response rates, counting all patients with a
response detected at or before the speciﬁed time point as responders. All
response rates were calculated as raw proportions. Rates of freedom from
progression to AP/BP on treatment and OS were estimated using Kaplan–
Meier product limit estimates according to intent-to-treat principles.
Ethics
ENEST1st was conducted in accordance with the International Conference
on Harmonisation Harmonised Tripartite Guidelines for Good Clinical
Practice, the Declaration of Helsinki and applicable local regulations.
Eligible patients were included only after providing written consent and in
accordance with local laws and regulations. The protocol and informed
consent forms were reviewed and approved by an institutional
review board, independent ethics committee or research ethics board
before study start at each participating institution. ENEST1st was registered
in the EU Clinical Trials Registry (2009-017775-19) and ClinicalTrials.gov
(NCT01061177).
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RESULTS
Patients and treatment exposure
From 2010 to 2012, 1164 patients were screened, 1091 were
enrolled from 307 sites in 26 European countries (Supplementary
Figure S1; Supplementary Table S2) and 1089 received ⩾ 1 dose of
nilotinib 300 mg twice daily (Figure 1). The median age of treated
patients was 53 years (Table 1). The median time since diagnosis
was 0.9 months, and 70.3% of patients (n= 766) had received prior
treatment for CML (hydroxyurea, 52.9% (n= 576); imatinib, 17.3%
(n= 188); other, 0.2% (n= 2)). EUTOS risk scores were low and high
in 82.6% (n= 900) and 8.6% (n= 94) of patients, respectively; Sokal
risk scores were low, intermediate and high in 34.6% (n= 377),
37.5% (n= 408) and 18.1% (n= 197), respectively. EUTOS and Sokal
risk scores could not be calculated in 8.7% (n= 95) and 9.8%
(n= 107) of patients, respectively, owing to missing baseline data
for ⩾ 1 parameter required for the calculation.
A total of 80.9% of patients (n= 881) completed 24 months of
study treatment, and 19.1% (n= 208) discontinued before
24 months (Table 2). Dose changes or interruptions occurred in
45.2% of patients (n= 492), including 36.7% (n= 400) with changes
or interruptions owing to AEs or laboratory abnormalities.
Molecular and cytogenetic responses
Among patients in the molecular analysis population (n= 1052),
the rate of MR4 at 18 months was 38.4% (95% conﬁdence interval
(CI), 35.5–41.3%; n=404). Rates of MMR, MR4 and MR4.5 at 3, 12, 18
and 24 months are listed in Table 3. Cumulative rates of MMR, MR4
and MR4.5 by 24 months were 80.4% (n= 846), 55.2% (n= 581) and
38.6% (n=406), respectively (Figure 2a). Among patients remaining
on study at 18 and 24 months, 13.7% (121/886) and 9.2% (79/855)
had not achieved MMR by 18 or 24 months, respectively.
Patients with low EUTOS or Sokal risk scores were more likely
than those with higher scores to achieve MR4 (Figure 2b). At
24 months, MR4 rates (95% CI) among patients with low and high
EUTOS risk scores were 41.4% (38.2–44.7%; 363/876) and 27.8%
(18.5–37.0%; 25/90), respectively; MR4 rates (95% CI) at 24 months
were 44.7% (39.6–49.8%; 164/367), 39.7% (34.9–44.6%; 157/395),
and 31.4% (24.8–38.0%; 60/191) among patients with low
intermediate and high Sokal risk scores, respectively.
Among patients in the molecular analysis population with no
prior imatinib exposure (n= 872), 81.2% (n= 708), 55.5% (n= 484)
and 37.8% (n= 330) achieved MMR, MR4 and MR4.5, respectively,
by 24 months. Of patients in this subpopulation with evaluable 3-
month RQ-PCR assessments (n= 783; landmark analysis popula-
tion), 78.5% (n= 615), 18.5% (n= 145) and 2.9% (n= 23) had BCR-
ABL1IS⩽ 1%, BCR-ABL1IS41–⩽ 10% and BCR-ABL1IS410%, respec-
tively, at 3 months. Rates of MMR, MR4 and MR4.5 by 24 months
were the highest among patients with BCR-ABL1IS⩽ 1% at
3 months (excluding those with MMR (n= 241), MR4 (n= 46) or
MR4.5 (n= 14), respectively, at 3 months) and the lowest among
patients with BCR-ABL1IS410% at 3 months (Figure 3).
Patients in the intent-to-treat population with documented
Ph− BCR-ABL1+ disease at screening (n= 30) or with unconﬁrmed
Ph status at screening and no Ph+ metaphases detected at later
time points (n= 76) were excluded from the cytogenetic analysis
population. Among the remaining patients (n= 983), 67.3%
(95% CI, 64.4–70.3%; n= 662) achieved CCyR by 6 months and
82.5% (95% CI, 80.1–84.9%; n= 811) achieved CCyR by 12 months.
Survival and progression
Estimated OS at 24 months was 98.9% (95% CI, 98.0–99.4%), with
13 deaths reported on study (⩽24 months after ﬁrst dose of study
treatment). Four patients died ⩽ 28 days after the last dose of
study treatment/month 24 evaluation (one each due to pulmon-
ary embolism, congestive heart failure, thrombocytopenia and
infection), and nine patients died 428 days after the last dose of
study treatment/month 24 evaluation (three each due to
infections and secondary cancers and one each due to cerebral
infarction, heart failure and CML progression). Six patients (0.6%)
progressed to AP (n= 3) or BP (n= 3) on treatment, none of whom
Screening failure (n = 73)
Screened (n = 1164)
Enrolled (n = 1091)
ITT/safety population (N = 1089)
Reason for exclusion:
• Did not receive ≥ 1 dose of study drug (n = 2)
Completed 24 months of treatment (n = 881)
•
•
Landmark analysis population (n = 783)
Reason for exclusion:
Received ≤ 3 months imatinib therapy prior to enrollment (n = 180)
No evaluable 3-month BCR-ABL1 assessment (n = 89)
Molecular analysis population (n = 1052)
Typical BCR-ABL1 transcripts not detected at baseline (n = 33)
Received > 3 months imatinib therapy prior to enrollment (protocol violation; n = 4)
•
•
Reason for exclusion:
Cytogenetic analysis population (n = 983)
Reason for exclusion:
Documented Ph− BCR-ABL1+ CML-CP at
screening (n = 30)
Unconfirmed Ph status at screening and no Ph+
metaphases detected at later time points (n = 76)
•
•
Figure 1. Analysis populations. aThe original target enrollment of N= 806 (determined using an approximation of a normal distribution to
achieve a precision of 3.3% for the 95% CI of the primary end point, assuming an MR4 rate of 25% at 18 months, a discontinuation rate of 15%
and a Philadelphia chromosome-negative and/or atypical BCR-ABL1 transcript prevalence of 5%) was increased to allow a more robust analysis
of the study’s exploratory results. ITT, intent to treat.
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died on study. At 24 months, the estimated rate of freedom from
progression to AP/BP on treatment was 99.4% (95% CI, 98.7–99.7%).
Safety
Rash, pruritus and headache were the most common nonhema-
tological AEs, reported in 21.4% (n= 233), 16.5% (n= 180) and
15.2% (n= 166) of patients, respectively (Table 4). Pancreatitis,
hepatotoxicity and ﬂuid retention occurred in 1.0% (n= 11; grade
3/4, 0.6%), 1.4% (n= 15; grade 3/4, 0.4%) and 11.8% (n= 129; grade
3/4, 0.8%) of patients, respectively. Pleural effusion occurred in
0.6% (n= 7; grade 3/4, 0.2%) of patients; 1 patient with grade 3
pleural effusion was treated with imatinib before enrollment
(imatinib duration, 53 days). No patient was diagnosed with
pulmonary hypertension. Arrhythmia and supraventricular
arrhythmia were reported in 0.6% (n= 6) and 0.1% (n= 1) of
patients, respectively (including grade 3/4 arrhythmia in 1 patient).
Congestive heart failure was reported in 0.3% of patients (n= 3; all
grade 3). Ischemic cardiovascular events occurred in 6.0% of
patients (n= 65; grade 3/4, 3.5%), including peripheral artery
disease in 1.9% (n= 21; grade 3/4, 0.7%), ischemic heart disease in
Table 1. Demographic and baseline characteristics (ITT population;
N= 1089)
N= 1089
Median age (range), years 53 (18–91)
Sex, n (%)
Male 642 (59.0)
Female 447 (41.0)
White, n (%) 1045 (96.0)
Median time since diagnosis (range), months 0.9 (o0.1–6.6)a
Prior treatment for CML, n (%) 766 (70.3)
Imatinib 188 (17.3)
Hydroxyurea 576 (52.9)
Other 2 (0.2)
Median prior treatment duration (range), monthsb 0.9 (0.1–7.6)a
Cytogenetic classiﬁcation, n (%)
Ph+ 983 (90.3)
Ph− /BCR-ABL1+ 30 (2.8)
Unknown 76 (7.0)
Transcript type, n (%)
b2a2 and/or b3a2 1056 (97.0)
Otherc 16 (1.5)
Inadequate sample, not evaluated or not
reported
17 (1.6)
EUTOS risk, n (%)
Low 900 (82.6)
High 94 (8.6)
Missingd 95 (8.7)
Sokal risk, n (%)
Low 377 (34.6)
Intermediate 408 (37.5)
High 197 (18.1)
Missingd 107 (9.8)
Abbreviations: CML, chronic myeloid leukemia; EUTOS, European Treatment
and Outcome Study; ITT, intent to treat; Ph, Philadelphia chromosome. aOne
patient was pretreated with hydroxyurea while awaiting conﬁrmation of
CML diagnosis and, therefore, had a longer prior treatment duration than
time since diagnosis. Four patients with 43 months of prior exposure to
imatinib were excluded from the analysis of median and range; for these 4
patients, prior treatment durations were 93, 114, 117 and ⩾ 1089 days,
respectively. bAmong patients with prior CML treatments. cIncluding e1a2,
e19a2, e14a3, e18a2, e8a2 and e13a3. dEUTOS and/or Sokal risk scores could
not be calculated for patients with missing data for baseline parameters
required for the calculation of these scores.
Table 2. Patient disposition and treatment exposure (safety
population; N= 1089)
Patients, n (%) N= 1089
Completed ⩾ 24 months of treatment 881 (80.9)
Discontinued treatmenta 208 (19.1)
Adverse event 117 (10.7)
Withdrew consentb 27 (2.5)
Disease progression/treatment failure 17 (1.6)
Abnormal laboratory value 6 (0.6)
Abnormal test procedure result 4 (0.4)
Otherc 37 (3.4)
Median duration of exposure
(25th–75th percentile), daysd
722 (691–734)
Median nilotinib dose intensity
(25th–75th percentile), mg/daye
600 (588–600)
Patients with dose interruption, n (%) 387 (35.5)
Median number of interruptions per patient
(25th–75th percentile)
1 (1–2)
Median duration of interruption (25th–75th
percentile), days
14 (7–30)
Patients with dose reduction, n (%) 321 (29.5)
Maximal dose reduction, n (%)
To 450mg/day 22 (2.0)
To 400mg/day 2 (0.2)
To 300mg/day 263 (24.2)
To 150mg/day 34 (3.1)
Total patients with dose change/interruption, n (%) 492 (45.2)
Reason for dose change/interruption
Adverse event/laboratory abnormality 400 (36.7)
Dosing errorf 123 (11.3)
Scheduling conﬂictf 72 (6.6)
Dispensing error 32 (2.9)
aReasons for discontinuation are listed as reported by the investigator.
bWithdrawal of consent was due to treatment failure in 2 patients (1.8%).
cIncludes discontinuations owing to protocol deviation (n= 11), loss to
follow-up (n= 9), new cancer therapy (n= 9; chronic myeloid leukemia
(n= 7) and endometrial cancer and non-Hodgkin lymphoma (n= 1 each)),
administrative problems (n= 4) and death (n= 4). dExcluding periods of
drug interruption. eDeﬁned as the sum of all doses administered divided
by the time on treatment (including periods of drug interruption). fReasons
for dosing error and scheduling conﬂict included commercial drug
dispensed or delayed medication return by patient.
Table 3. Rates of MMR, MR4 and MR4.5 at 3, 12, 18 and 24 months
(molecular analysis population; n= 1052)
3 months 12 months 18 months 24 months
MMR, n (%) 312 (29.7) 592 (56.3) 692 (65.8) 644 (61.2)
95% CI 26.9–32.4 53.3–59.3 62.9–68.6 58.3–64.2
MR4, n (%) 66 (6.3) 324 (30.8) 404 (38.4) 425 (40.4)
95% CI 4.8–7.7 28.0–33.6 35.5–41.3 37.4–43.4
MR4.5, n (%) 20 (1.9) 161 (15.3) 220 (20.9) 231 (22.0)
95% CI 1.1–2.7 13.1–17.5 18.5–23.4 19.5–24.5
Abbreviations: CI, conﬁdence interval; MMR, major molecular response
(BCR-ABL1IS⩽ 0.1%); MR4, molecular response 4 (BCR-ABL1IS⩽ 0.01%); MR4.5,
molecular response 4.5 (BCR-ABL1IS⩽ 0.0032%).
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3.4% (n= 37; grade 3/4, 2.2%) and ischemic cerebrovascular events
in 0.8% (n= 9; grade 3/4, 0.6%). Four patients died due to ischemic
cardiovascular events, one each due to congestive heart failure,
cerebral infarction, heart failure and ischemic stroke (the death
due to ischemic stroke occurred 424 months after ﬁrst dose of
study drug; therefore, it was not considered in the OS analysis).
Grade 3/4 thrombocytopenia and neutropenia were reported in
6.0% (n= 65) and 4.8% (n= 52) of patients, respectively (Table 5).
Grade 3/4 biochemical abnormalities of decreased phosphate
level and increased lipase activity occurred in 14.3% (n= 156) and
7.2% (n= 78) of patients, respectively.
Because routine monitoring of lipid and glucose levels was not
mandated in the study protocol, the frequencies of hypercholes-
terolemia, hyperglycemia and diabetes mellitus on study could
not be evaluated; however, AEs of hypercholesterolemia, hyper-
glycemia and diabetes mellitus were spontaneously reported in
3.0% (n= 33), 3.3% (n= 36) and 1.2% (n= 13) of patients,
respectively.
DISCUSSION
ENEST1st was the ﬁrst study to investigate deep molecular
response as the primary end point. Results from this study conﬁrm
the high rates of deep responses achieved with frontline nilotinib;
38.4% of patients in the molecular analysis population achieved
the primary end point of MR4 at 18 months, and by 24 months,
55.2% achieved MR4 and 38.6% achieved MR4.5. Although the
most appropriate molecular response threshold for attempting
TFR remains under investigation, the feasibility of TFR following
achievement of a sustained, deep molecular response on nilotinib
has been demonstrated,11 and ongoing studies are evaluating TFR
in patients with sustained MR4 or MR4.5 on nilotinib.12,13 The high
rates of MR4 and MR4.5 in ENEST1st suggest that many patients
treated with frontline nilotinib may be able to achieve the level of
response necessary to qualify for such studies.
In addition to enabling the possibility of TFR, deep molecular
responses have been linked to improved patient outcomes,
including prolonged survival and decreased risk of disease
progression.18–20 In a recent study of patients treated with
frontline imatinib, those with MR4 at 24 months had a 0%
estimated incidence of leukemia-related death by 6 years vs 7%
for patients without MR4 at 24 months (P= 0.004).21 Although
many imatinib-treated patients eventually attain deep molecular
responses with long-term therapy,21,22 results from ENESTnd
demonstrated that patients achieved faster and higher rates of
such responses with frontline nilotinib vs imatinib.3–7
The use of the EUTOS laboratory network to assess molecular
responses in ENEST1st demonstrated the feasibility of noncen-
tralized, regional molecular monitoring, provided that standar-
dized and sensitive assays are used and deﬁnitions are
harmonized.16 Through the work of the EUTOS Study Group,
recommendations for standardized scoring of deep molecular
responses have been developed, which will allow for more
consistent patient management across local and regional treat-
ment centers.23 As ENEST1st was the ﬁrst study to assess nilotinib
efﬁcacy according to EUTOS risk scores, these results validate the
use of this newer risk score for assessing patient prognosis at
baseline.14 Importantly, data from a EUTOS population-based
registry of 2904 patients with CML (94.3% with CML-CP) suggest
that the age, sex and EUTOS risk score distribution of patients in
ENEST1st were generally similar to what is observed in routine
clinical practice.24
Patients in ENEST1st were slightly older than those in the
nilotinib 300-mg twice-daily arm of ENESTnd (median age of 53
years in ENEST1st vs 47 years in ENESTnd); however, the
distribution of Sokal risk scores was similar (72% of patients in
each study had low or intermediate Sokal risk scores).5 None-
theless, molecular response rates were higher in ENEST1st than in
ENESTnd; in ENEST1st, 81, 56 and 38% of patients without prior
imatinib exposure (the subpopulation most comparable to
patients in ENESTnd) achieved MMR, MR4 and MR4.5, respectively,
by 2 years, compared with 71, 39 and 25% of patients,
respectively, in the nilotinib 300-mg twice-daily arm of
ENESTnd.4 This difference may be due in part to improvements
in the management of nilotinib-treated patients, that is, a learning
effect in the period since ENESTnd was initiated (in 2007).5 For
example, whereas the ENESTnd protocol called for dose reduction
to nilotinib 400mg once daily after the ﬁrst or second occurrence
of study drug-related AEs, and permanent discontinuation after
the next occurrence,5 new dose reduction guidelines in ENEST1st
allowed for stepwise or temporary dose reductions to nilotinib 450
or 300 mg daily in patients with recurrent AEs, which may have
enabled patients to receive a more optimal nilotinib dose. In the
nilotinib 300-mg twice-daily arm of ENESTnd, 55% of patients had
dose interruptions/reductions owing to AEs by the 2-year data
cutoff, and the median dose intensity was 594mg/day (25th–75th
percentile, 553–600mg/day).4 By comparison, 36.7% of patients in
ENEST1st had dose changes or interruptions owing to AEs/
laboratory abnormalities, and the 25th percentile for dose
intensity was 35mg/day higher than that in ENESTnd.
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Figure 2. Cumulative molecular response rates. Raw cumulative
incidence (95% CI) of (a) MMR (BCR-ABL1IS⩽ 0.1%), MR4
(BCR-ABL1IS⩽ 0.01%) and MR4.5 (BCR-ABL1IS⩽ 0.0032%) in the
molecular analysis population (n= 1052) and (b) MR4 according
to European Treatment and Outcome Study (EUTOS) and Sokal
risk scores at diagnosis.
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Consistent with prior studies,2,25–27 ENEST1st demonstrated the
importance of early molecular response to frontline treatment.
Patients with BCR-ABL1IS⩽ 1% at 3 months achieved the highest
rates of response at later time points, whereas no patient with
BCR-ABL1IS410% at 3 months achieved MR4 by 24 months.
Because of the known association between early molecular
response and long-term outcomes, both the European Leukemia-
Net and the National Comprehensive Cancer Network recommend
BCR-ABL1IS⩽ 10% as a target response at 3 months.28,29 Nearly all
patients (97%) in the ENEST1st landmark analysis population
achieved this target, consistent with results from ENESTnd.2
Although achievement of BCR-ABL1IS⩽ 1% at 3 months is not a
designated treatment goal in current CML guidelines,28,29 the
results reported here are consistent with those reported elsewhere
in demonstrating the value of this landmark for predicting future
achievement of deep molecular response.2,18 In addition to
absolute BCR-ABL1IS levels at 3 months, some studies have shown
that the rate of decline in BCR-ABL1 levels early during treatment
may provide a further indication of expected long-term
outcomes.30–32 Branford et al.31 demonstrated that, among
patients with BCR-ABL1IS410% at 3 months, those with a BCR-
ABL1 halving time of 476 days had poorer long-term outcomes
than those with a halving time of ⩽ 76 days, while Hanfstein
et al.30 showed that the reduction in BCR-ABL1 transcript levels at
3 months relative to each patient’s individual baseline level was a
signiﬁcant predictor of survival.
Safety results from ENEST1st were similar to those of
ENESTnd,3–7 with no new safety signals identiﬁed. However,
although patients in ENEST1st were older than patients in
ENESTnd,5 the frequencies of some AEs, including rash and grade
Figure 3. Cumulative molecular response rates according to
3-month BCR-ABL1IS. (a) Raw cumulative rates (95% CI) of MMR
(BCR-ABL1IS⩽ 0.1%), (b) MR4 (BCR-ABL1IS⩽ 0.01%) and (c) MR4.5
(BCR-ABL1IS⩽ 0.0032%) among patients in the landmark analysis
population (n = 783) with BCR-ABL1IS⩽ 1%, 41–⩽ 10% and 410%
at 3 months. Patients who had already achieved MMR, MR4 or MR4.5,
respectively, at 3 months were excluded from the landmark analyses
of MMR, MR4 and MR4.5 rates over time.
Table 4. Nonhematological adverse events occurring in ⩾ 5.0% of
patients at any grade or ⩾ 1% of patients at grade 3/4 (safety
population; N= 1089)
Patients, n (%)a Total (all grades) Grade 2 Grade 3 Grade 4
Rash 233 (21.4) 53 (4.9) 4 (0.4) 0
Pruritus 180 (16.5) 48 (4.4) 3 (0.3) 0
Headache 166 (15.2) 43 (3.9) 8 (0.7) 0
Abdominal pain 160 (14.7) 54 (5.0) 8 (0.7) 0
Fatigue 151 (13.9) 45 (4.1) 7 (0.6) 0
Nausea 123 (11.3) 37 (3.4) 5 (0.5) 0
Alopecia 115 (10.6) 15 (1.4) 1 (0.1) 0
Nasopharyngitis 113 (10.4) 28 (2.6) 0 0
Myalgia 99 (9.1) 20 (1.8) 3 (0.3) 0
Arthralgia 97 (8.9) 30 (2.8) 2 (0.2) 0
Asthenia 97 (8.9) 25 (2.3) 2 (0.2) 0
Diarrhea 94 (8.6) 22 (2.0) 2 (0.2) 0
Dry skin 93 (8.5) 19 (1.7) 0 0
Muscle spasms 93 (8.5) 13 (1.2) 0 0
Back pain 80 (7.3) 26 (2.4) 4 (0.4) 0
Constipation 67 (6.2) 21 (1.9) 1 (0.1) 0
Arterial hypertension 65 (6.0) 31 (2.8) 12 (1.1) 0
Vomiting 65 (6.0) 22 (2.0) 2 (0.2) 1 (0.1)
Cough 56 (5.1) 13 (1.2) 1 (0.1) 0
Insomnia 55 (5.1) 15 (1.4) 2 (0.2) 0
Pain in extremity 54 (5.0) 16 (1.5) 2 (0.2) 0
aExcluding events that started 428 days after last dose of study drug or
month 24.
70
60
50
40
20
10
0 9 12 15 18 21
0
30
24
80
90
100
63
Transcript Level at 3 Months
BCR-ABL1 > 0.1% to ≤ 1% (n = 374)
BCR-ABL1 > 1% to ≤ 10% (n = 145)
BCR-ABL1 > 10% (n = 23)
By 12 months By 18 months By 24 months
74.6%
(70.2%-79.0%)
85.8%
(82.3%-89.4%)
29.7%
(22.2%-37.1%)
43.4%
(35.4%-51.5%)
55.9%
(47.8%-63.9%)
8.7%
(0%-20.2%)
21.7%
(4.9%-38.6%)
34.8%
(15.3%-54.2%)
Cu
m
ul
at
iv
e 
In
ci
de
nc
e 
of
 M
M
R,
 %
Time Since Study Entry, Months
88.5%
(85.3%-91.7%)
By 12 months By 18 months By 24 months
70
60
50
40
20
10
0 9 12 15 18 21
0
30
24
80
90
100
63
Cu
m
ul
at
iv
e 
In
ci
de
nc
e 
of
 M
R4
, %
Cu
m
ul
at
iv
e 
In
ci
de
nc
e 
of
 M
R4
.5
, %
42.7%
(38.6%-46.8%)
55.7%
(51.6%-59.8%)
65.0%
(61.1%-68.9%)
8.3%
(3.8%-12.8%)
0%
20.0%
(13.5%-26.5%)
24.1%
(17.2%-31.1%)
0% 0%
Time Since Study Entry, Months
Transcript Level at 3 Months
BCR-ABL1 > 0.01% to ≤ 1% (n = 569)
BCR-ABL1 > 1% to ≤ 10% (n = 145)
BCR-ABL1 > 10% (n = 23)
By 12 months By 18 months By 24 months
70
60
50
40
20
10
0 9 12 15 18 21
0
30
24
80
90
100
63
24.8%
(21.3%-28.2%)
38.1%
(34.2%-42.0%)
45.8%
(41.8%-49.7%)
4.1%
(0.9%-7.4%)
9.0%
(4.3%-13.6%)
14.5%
(8.8%-20.2%)
0%0% 0%
Time Since Study Entry, Months
Transcript Level at 3 Months
BCR-ABL1 > 0.0032% to ≤ 1% (n = 601)
BCR-ABL1 > 1% to ≤ 10% (n = 145)
BCR-ABL1 > 10% (n = 23)
ENEST1st study of frontline nilotinib in CML
A Hochhaus et al
6
Leukemia (2015), 1 – 8 © 2015 Macmillan Publishers Limited
3/4 thrombocytopenia and neutropenia, were lower in ENEST1st
(reported frequencies in the nilotinib 300-mg twice-daily arm of
ENESTnd by the 2-year data cutoff: rash, 41%; grade 3/4
thrombocytopenia, 10%; grade 3/4 neutropenia, 12%).4 The
relatively low frequencies of these common AE types further
supports the notion that patients in ENEST1st were more
optimally managed than patients in earlier studies—a frequent
occurrence as experience is gained with cancer therapies.33–35
Although baseline cardiovascular risk factors were not collected in
ENEST1st, the observed frequency of ischemic cardiovascular
events (6%) was comparable to what has been previously
reported for nilotinib-treated patients in ENESTnd.6 However, as
some patients in ENESTnd experienced cardiovascular events at
later time points (beyond the ﬁrst 2 years of treatment),6 it is
possible that the total frequency of such events in ENEST1st would
increase with longer follow-up.
Nilotinib treatment is known to be associated with certain
biochemical abnormalities, including hyperglycemia and hyper-
cholesterolemia.3–7 Because glucose and lipid monitoring was not
mandated in the ENEST1st protocol, the frequencies of glucose and
lipid abnormalities are unknown; the rates of spontaneously
reported hyperglycemia, hypercholesterolemia and diabetes melli-
tus likely underestimate the true frequency of these events. For
patients treated with nilotinib, it is recommended that lipid and
glucose levels be monitored before initiating treatment and during
treatment, and all cardiovascular risk factors should be monitored
and actively managed according to standard guidelines.1
The high rates of response and very low rate of progression to
AP/BP (0.6%) in ENEST1st demonstrate the efﬁcacy of frontline
nilotinib for the majority of patients; indeed, among patients
remaining on treatment at 24 months, only 9.2% had not achieved
MMR. However, 19.1% of patients discontinued treatment before
the 24-month assessment, clearly indicating that further improve-
ments in the frontline management of patients with CML-CP are
needed. Overall, results from ENEST1st, including those reported
here and data from 11 substudies directed by national and
international study groups, provide further support for the use of
nilotinib 300 mg twice daily as a frontline treatment option for
patients with newly diagnosed CML-CP.
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